OBJECTIVE: The standard therapy for advanced hepatocellular carcinoma (HCC) is sorafenib, with most patients experiencing disease progression within 6 months. Label-retaining cancer cells (LRCC) represent a novel subpopulation of cancer stem cells (CSC). The objective was to test whether LRCC are resistant to sorafenib. METHODS: We tested human HCC derived LRCC and non-LRCC before and after treatment with sorafenib. RESULTS: LRCC derived from human HCC are relatively resistant to sorafenib. The proportion of LRCC in HCC cell lines is increased after sorafenib while the general population of cancer cells undergoes growth suppression. We show that LRCC demonstrate improved viability and toxicity profiles, and reduced apoptosis, over non-LRCC. We show that after treatment with sorafenib, LRCC upregulate the CSC marker aldehyde dehydrogenase 1 family, wingless-type MMTV-integration-site family, cell survival and proliferation genes, and downregulate apoptosis, cell cycle arrest, cell adhesion and stem cells differentiation genes. This phenomenon was accompanied by non-uniform activation of specific isoforms of the sorafenib target proteins extracellular-signal-regulated kinases and v-akt-murine-thymoma-viral-oncogene homologue (AKT) in LRCC but not in non-LRCC. A molecular pathway map for sorafenib treated LRCC is proposed. CONCLUSIONS: Our results suggest that HCC derived LRCC are relatively resistant to sorafenib. Since LRCC can generate tumours with as few as 10 cells, our data suggest a potential role for these cells in disease recurrence. Further investigation of this phenomenon might provide novel insights into cancer biology, cancer recurrence and drug resistance with important implications for the development of novel cancer therapies based on targeting LRCC.
OBJECTIVE: The standard therapy for advanced hepatocellular carcinoma (HCC) is sorafenib, with most patients experiencing disease progression within 6 months. Label-retaining cancer cells (LRCC) represent a novel subpopulation of cancer stem cells (CSC). The objective was to test whether LRCC are resistant to sorafenib. METHODS: We tested humanHCC derived LRCC and non-LRCC before and after treatment with sorafenib. RESULTS:LRCC derived from humanHCC are relatively resistant to sorafenib. The proportion of LRCC in HCC cell lines is increased after sorafenib while the general population of cancer cells undergoes growth suppression. We show that LRCC demonstrate improved viability and toxicity profiles, and reduced apoptosis, over non-LRCC. We show that after treatment with sorafenib, LRCC upregulate the CSC marker aldehyde dehydrogenase 1 family, wingless-type MMTV-integration-site family, cell survival and proliferation genes, and downregulate apoptosis, cell cycle arrest, cell adhesion and stem cells differentiation genes. This phenomenon was accompanied by non-uniform activation of specific isoforms of the sorafenib target proteins extracellular-signal-regulated kinases and v-akt-murine-thymoma-viral-oncogene homologue (AKT) in LRCC but not in non-LRCC. A molecular pathway map for sorafenib treated LRCC is proposed. CONCLUSIONS: Our results suggest that HCC derived LRCC are relatively resistant to sorafenib. Since LRCC can generate tumours with as few as 10 cells, our data suggest a potential role for these cells in disease recurrence. Further investigation of this phenomenon might provide novel insights into cancer biology, cancer recurrence and drug resistance with important implications for the development of novel cancer therapies based on targeting LRCC.
Entities:
Keywords:
Cancer; Cell Proliferation; Drug Resistance; Hepatocellular Carcinoma; Stem Cells
Authors: Vanessa Rausch; Li Liu; Georgios Kallifatidis; Bernd Baumann; Jürgen Mattern; Jury Gladkich; Thomas Wirth; Peter Schemmer; Markus W Büchler; Margot Zöller; Alexei V Salnikov; Ingrid Herr Journal: Cancer Res Date: 2010-06-08 Impact factor: 12.701
Authors: Roberto Gedaly; Paul Angulo; Jonathan Hundley; Michael F Daily; Changguo Chen; Alvaro Koch; B Mark Evers Journal: Anticancer Res Date: 2010-12 Impact factor: 2.480
Authors: Reiichiro Kuwahara; Alexander V Kofman; Charles S Landis; E Scott Swenson; Els Barendswaard; Neil D Theise Journal: Hepatology Date: 2008-06 Impact factor: 17.425
Authors: Romuald Binet; Damien Ythier; Ana I Robles; Manuel Collado; Delphine Larrieu; Claire Fonti; Elisabeth Brambilla; Christian Brambilla; Manuel Serrano; Curtis C Harris; Rémy Pedeux Journal: Cancer Res Date: 2009-12-15 Impact factor: 12.701
Authors: Margaret A Park; Guo Zhang; Aditi Pandya Martin; Hossein Hamed; Clint Mitchell; Philip B Hylemon; Martin Graf; Mohamed Rahmani; Kevin Ryan; Xiang Liu; Sarah Spiegel; James Norris; Paul B Fisher; Steven Grant; Paul Dent Journal: Cancer Biol Ther Date: 2008-10-12 Impact factor: 4.742
Authors: David Capper; Timo Gaiser; Christian Hartmann; Antje Habel; Wolf Mueller; Christel Herold-Mende; Andreas von Deimling; Markus David Siegelin Journal: Acta Neuropathol Date: 2009-02-12 Impact factor: 17.088
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Kan Chen; Wanlu Cao; Juan Li; Dave Sprengers; Pratika Y Hernanda; Xiangdong Kong; Luc Jw van der Laan; Kwan Man; Jaap Kwekkeboom; Herold J Metselaar; Maikel P Peppelenbosch; Qiuwei Pan Journal: Mol Med Date: 2015-10-13 Impact factor: 6.354
Authors: T Nakatsuka; K Tateishi; Y Kudo; K Yamamoto; H Nakagawa; H Fujiwara; R Takahashi; K Miyabayashi; Y Asaoka; Y Tanaka; H Ijichi; Y Hirata; M Otsuka; M Kato; J Sakai; M Tachibana; H Aburatani; Y Shinkai; K Koike Journal: Oncogene Date: 2017-07-10 Impact factor: 9.867